Endocannabinoid System and TRPV1 Receptors in the Dorsal Hippocampus of the Rats Modulate Anxiety-like Behaviors

Document Type: Original Article


1 Physiology-Pharmacology Research Centre, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

2 Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran

3 Department of Biology, Faculty of Basic Sciences, University of Mazandaran, Babolsar, Iran


Fatty acid is amide hydrolase which reduce endogenous anandamide. Transient receptor potential vanilloid-1 (TRPV1) channels have been reported to have a role in the modulation of anxiety-like behaviors in rodents. In the present study, the effects of either endocannabinoid system or TRPV1 channels and their possible interaction on anxiety-like behaviors of the rats were explored.
Materials and Methods
Elevated plus-maze test of anxiety was used to induce anxiety. Capsaicin and AMG 9810 as TRPV1 agonist and antagonist respectively were injected into the dorsal hippocampus. URB 597 as selective FAAH inhibitor and AM 251 as CB1 receptor selective antagonist were also injected into the dorsal hippocampus. The effect of AMG 9810 on the response of URB 597 was also examined.
Intra-CA1 injection of URB 597 (0.001, 0.01 and 0.1 µg/rat) and AMG 9810 (0.003, 0.03 and 0.3 µg/rat) produced anxiolytic-like effects. Intra-CA1 infusion of capsaicin (0.003, 0.03 and 0.3 µg/rat) increased the anxiety-related behaviors and AM 251 (0.001, 0.01 and 0.1 µg/rat) did not significantly change the animals behavior. AMG 9810 at the dose of 0.003 µg/rat did not change the anxiolytic-like effect of URB 597.
The results of the present study demonstrated that both endocannabinoid system and TRPV1 receptors may affect anxiety-like behaviors. In addition, it seems that TRPV1 receptors are not involved in the effects of anandamide on anxiety-related behaviors in the CA1 region.


1. Iversen L. Cannabis and the brain. Brain 2003; 126:1252-1270.

2. Fernández-Ruiz J, Berrendero F, Hernández ML, Ramos JA. The endogenous cannabinoid system and brain development. Trends Neurosci 2000; 23:14-20.

3. Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 2005; 81:331-342.

4. McKinney MK, Cravatt BF. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 2005; 74:411-32.

5. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, et al.  Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003; 9:76-81.

6. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997; 23:816-24.

7. Moran MM, McAlexander MA, Bíró T, Szallasi A. Transient receptor potential channels as therapeutic targets. Nat Rev Drug Discov 2011; 10:601-620.

8. Mezey E, Tóth ZE, Cortright DN, Arzubi MK, Krause JE, Elde R, et al.  Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci 2000; 97:3655-3660.

9. Tóth A, Boczán J, Kedei N, Lizanecz E, Bagi Z, Papp Z, et al. Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain. Brain Res Mol Brain Res 2005; 135:162-168.

10. Kasckow JW, Mulchahey JJ, Geracioti TD Jr. Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28:291-295.

11. Di Marzo V. Anandamide serves two masters in the brain. Nat Neurosci 2010; 13:1446-1448.

12. Vaughan CW, Connor M, Bagley EE, Christie MJ. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol 2000; 57:288-295.

13. Xing J, Li J. TRPV1 receptor mediates glutamatergic synaptic input to dorsolateral periaqueductal gray (dl-PAG) neurons. J Neurophysiol 2007; 97:503-511.

14. Tsou K, Nogueron MI, Muthian S, Sañudo-Pena MC, Hillard CJ, Deutsch DG, et al. Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. Neurosci Lett 1998; 254:137-140.

15. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates, 4th ed. Academic Press San Diego. 1998.

16. Roohbakhsh A, Hajizadeh Moghaddam A, Mahmoodi Delfan K. Anxiolytic-like effect of testosterone in male rats: GABAC receptors are not involved. Iran J Basic Med Sci  2011; 14:376-382.

17. Roohbakhsh A, Keshavarz S, Hasanein P, Rezvani ME, Moghaddam AH.Role of endocannabinoid system in the ventral hippocampus of rats in the modulation of anxiety-like behaviours. Basic Clin Pharmacol Toxicol 2009; 105:333-338.

18. Rezayat M, Roohbakhsh A, Zarrindast MR, Massoudi R, Djahanguiri B. Cholecystokinin and GABA interaction in the dorsal hippocampus of rats in the elevated plus-maze test of anxiety. Physiol Behav  2005; 84:775-782.

19. Rubino T, Realini N, Castiglioni C, Guidali C, Viganó D, Marras E, et al. Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb cortex  2008; 18:1292-1301.

20.Terzian AL, Aguiar DC, Guimarães FS, Moreira FA. Modulation of anxiety-like behaviour by transient receptor potential vanilloid type 1 (TRPV1) channels located in the dorsolateral periaqueductal gray. Eur Neuropsychopharmacol 2009; 19:188-195.

21. Pitcher MH, Price TJ, Entrena JM, Cervero F. Spinal NKCC1 blockade inhibits TRPV1-dependent referred allodynia. Mol Pain 2007; 30:3:17.

22. Moise AM, Eisenstein SA, Astarita G, Piomelli D, Hohmann AG. An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters. Psychopharmacology 2008; 200:333-346.

23. Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A, et al. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry  2007; 62:1103-1110.

24. Murillo-Rodríguez E, Vázquez E, Millán-Aldaco D, Palomero-Rivero M, Drucker-Colin R. Effects of the fatty acid amide hydrolase inhibitor URB597 on the sleep-wake cycle, c-Fos expression and dopamine levels of the rat. Eur J Pharmacol 2007; 562:82-91.

25. Ognibene E, Adriani W, Laviola G. Anxiolytic and reward-related properties of URB597, a novel FAAH inhibitor, in CD1 mice. Eur Neuropsychopharmacol 2006; 16:S460.

26. Moreira FA, Aguiar DC, Guimarães FS. Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. Neuropharmacology 2007; 52:958–965.

27. Hill MN, Karacabeyli ES, Gorzalka BB. Estrogen recruits the endocannabinoid system to modulate emotionality. Psychoneuroendocrinology 2007; 32:350-357.

28. Arevalo C, de Miguel R, Hernandez-Tristan R. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol Biochem Behav 200; 70:123–131.

29. Navarro M, Hernandez E, Munoz RM, del Arco R, Villanua MA, Carrera MRA, et al.  Acute administration of CB1 cannabinoid receptor antagonist SR141716A induces anxiety-like responses in the rat. Neuroreport 1997; 8:491–496.

30. Akinshola BE, Chakrabarti A, Onaivi ES. In vitro and in vivo action of cannabinoids. Neurochem Res 1999; 24:1233–1240.

31. Haller J, Bakos N, Szimay M, Ledent C, Freund TF. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 2002; 16:1395–1398.

32. Numazaki M, Tominaga T, Takeuchi K, Murayama N, Toyooka H, Tominaga M. Structural determinant of TRPV1 desensitization interacts with calmodulin. Proc Natl Acad Sci 2003; 24:8002-8006.

33. Santos CJ, Stern CA, Bertoglio LJ. Attenuation of anxiety-related behaviour after the antagonism of transient receptor potential vanilloid type 1 channels in the rat ventral hippocampus. Behav Pharmacol 2008; 19:357-360.

34. Marsch R, Foeller E, Rammes G, Bunck M, Kössl M, Holsboer F, et al. Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. J Neurosci 2007; 27:832-839.

35. Gavva NR, Tamir R, Qu Y, Klionsky L, Zhang TJ, Immke D, et al. AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 2005; 313:474-484.

36. Malinowska B, Kwolek G, Göthert M. Anandamide and methanandamide induce both vanilloid VR1- and cannabinoid CB1 receptor-mediated changes in heart rate and blood pressure in anaesthetized rats. Naunyn Schmiedebergs Arch Pharmacol 2001; 364:562-569.

37. de Lago E, de Miguel R, Lastres-Becker I, Ramos JA, Fernández-Ruiz J. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and  in vitro evidence. Brain Res 2004; 1007:152-159.

38. Sulcova E, Mechoulam R, Fride E. Biphasic effects of anandamide. Pharmacol Biochem Behav 1998; 59:347-352.

39. Micale V, Cristino L, Tamburella A, Petrosino S, Leggio GM, Drago F, et al. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 2009; 34:593-606.